- Home
- CABA vs DIBS Comparison
CABA vs DIBS Comparison
Compare CABA & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- DIBS
- Stock Information
- Founded
- CABA 2017
- DIBS 2000
- Country
- CABA United States
- DIBS United States
- Employees
- CABA N/A
- DIBS N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- DIBS Catalog/Specialty Distribution
- Sector
- CABA Health Care
- DIBS Consumer Discretionary
- Exchange
- CABA Nasdaq
- DIBS Nasdaq
- Market Cap
- CABA 210.0M
- DIBS 175.8M
- IPO Year
- CABA 2019
- DIBS 2021
- Fundamental
- Price
- CABA $3.03
- DIBS $3.96
- Analyst Decision
- CABA Strong Buy
- DIBS Buy
- Analyst Count
- CABA 10
- DIBS 1
- Target Price
- CABA $28.50
- DIBS $8.00
- AVG Volume (30 Days)
- CABA 1.1M
- DIBS 106.0K
- Earning Date
- CABA 11-14-2024
- DIBS 11-08-2024
- Dividend Yield
- CABA N/A
- DIBS N/A
- EPS Growth
- CABA N/A
- DIBS N/A
- EPS
- CABA N/A
- DIBS N/A
- Revenue
- CABA N/A
- DIBS $86,409,000.00
- Revenue This Year
- CABA N/A
- DIBS $5.82
- Revenue Next Year
- CABA N/A
- DIBS $7.96
- P/E Ratio
- CABA N/A
- DIBS N/A
- Revenue Growth
- CABA N/A
- DIBS N/A
- 52 Week Low
- CABA $2.96
- DIBS $3.81
- 52 Week High
- CABA $26.35
- DIBS $6.30
- Technical
- Relative Strength Index (RSI)
- CABA 32.06
- DIBS 34.42
- Support Level
- CABA $4.33
- DIBS $3.97
- Resistance Level
- CABA $4.49
- DIBS $4.16
- Average True Range (ATR)
- CABA 0.38
- DIBS 0.12
- MACD
- CABA -0.07
- DIBS -0.02
- Stochastic Oscillator
- CABA 3.91
- DIBS 6.52
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company's single reportable and operating segment contains two reporting units; 1stDibs, which consists of the company's online marketplace that enables commerce between sellers and buyers; and Design Manager, which is the company's separate online platform that is used to sell a software solution to interior designers. It generates revenue primarily from fees from seller marketplace services as well as other services, including advertisements and software services.